FrançaisAre analysts right about Abbott Laboratories (ABT)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For Abbott Laboratories, we replayed every analyst price target of the past 12 months and measured the real outcome: 32% were profitable, average return +6% (308 calls). At 3 months: +1% average return (29% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Morgan Stanley | 30 | 40% | +10% |
| Raymond James | 28 | 32% | +6% |
| Jefferies | 27 | 41% | +9% |
| Citigroup | 26 | 27% | +1% |
| Wells Fargo | 26 | 23% | +4% |
Valuation
Is Abbott Laboratories overvalued, and is it a good time to buy Abbott Laboratories right now? If you're wondering, here's a recap to make up your own mind: Abbott Laboratories's valuation vs its sector median, to weigh alongside analyst reliability (above) and past performance. Educational information, not buy advice.
The P/E (price ÷ earnings per share) = how many years of earnings you pay for the stock. The higher it is, the more growth the market expects — but the pricier the stock, so more vulnerable if growth disappoints. The forward P/E uses next year's expected earnings: lower than the current P/E = rising expected earnings. We compare it to the sector median to see whether the stock is expensive relative to its peers.
| Metric | Abbott Laboratories | Sector median (Health Care) |
|---|---|---|
| P/E | 37.0 | 29.4 |
| Forward P/E | 18.4 | 17.1 |
| Net margin | 12% | 12% |
👉 Abbott Laboratories trades above its sector median (37.0 vs 29.4) — the market expects higher growth; watch out for disappointment.
📖 P/E, PEG, margin…: see the glossary
💵 Dividend : Abbott Laboratories pays about $2.44/share/yr → 2.65% yield. what is this?
Frequently asked questions
Is Abbott Laboratories a buy right now?
The analyst consensus on Abbott Laboratories (ABT) is "Buy" (53 bullish, 0 bearish calls over 12 months). This is not advice: historically, 32% of their targets on this stock turned out profitable over 1 year.
What is Abbott Laboratories's price target?
The median 12-month price target is $120 (+8% vs $112), ranging from $112 to $143 (17 analysts).
Are analysts accurate on Abbott Laboratories?
Over 1 year, 32% of analyst targets on Abbott Laboratories were profitable, for an average return of +6% (across 308 timestamped calls). This is JPI Invest's accuracy metric.
What is the Abbott Laboratories stock forecast?
Analysts target a median of $120 within 12 months, i.e. +8% vs the current price. The most bullish targets $143, the most cautious $112.
What is the Abbott Laboratories stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $120, +8%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (32%), and the stock's past trajectory.
Is Abbott Laboratories overvalued?
Its P/E is 37.0, forward P/E 18.4. A forward P/E lower than the current P/E means earnings are expected to grow.
📊 See the full interactive analysis of Abbott Laboratories →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.